Arrivent Biopharma (NASDAQ: AVBP) net income
Arrivent Biopharma reported a net loss of $166.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $80.5m. Earnings per share were −$4.32.
Arrivent Biopharma's best year of the last 3 was fiscal 2023. It reported a loss in 3 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$166.3m | — | — | −$4.32 |
| 2024 | −$80.5m | — | — | −$2.56 |
| 2023 | −$69.3m | — | — | −$32.38 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arrivent Biopharma net income compared with its sector
By net income for its latest fiscal year, Arrivent Biopharma ranks 394th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 392nd | Nektar Therapeutics | −$164.1m | −297.1% |
| 393rd | Larimar Therapeutics | −$165.7m | — |
| 394th | Arrivent Biopharma | −$166.3m | — |
| 395th | Edgewise Therapeutics | −$167.8m | — |
| 396th | Cabaletta Bio | −$167.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Arrivent Biopharma
- How much did Arrivent Biopharma earn in fiscal 2025?
- Arrivent Biopharma reported a net loss of $166.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $80.5m.
- What are the earnings per share of Arrivent Biopharma?
- They were −$4.32 in fiscal 2025, compared with −$2.56 in fiscal 2024.
- Where does Arrivent Biopharma rank in its sector by net income?
- It ranks 394th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Arrivent Biopharma come from?
- From the annual report (Form 10-K) that Arrivent Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arrivent Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Arrivent Biopharma: the Arrivent Biopharma page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.